Series C - NiKang Therapeutics
Investment Firm
Overview
NiKang Therapeutics is a biotech company focused on discovering and developing small molecule oncology medicines.
Announced Date
May 26, 2021
Closed on Date
May 19, 2021
Funding Type
Series C
Highlights
Location
United States, North America
Social
Investor Lead
HBM Healthcare Investments
HBM Healthcare Investments is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.
Cormorant Asset Management
Cormorant Asset Management is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.
Octagon Capital Advisors
Octagon Capital Advisors is a private_equity and venture firm.
Participant Investors
18
Round Details and Background
NiKang Therapeutics raised $200000000 on 2021-05-26 in Series C
NiKang Therapeutics is a biotech company focused on discovering and developing small molecule oncology medicines.
Company Funding History
3
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Sep 14, 2020 |  Series B - NiKang Therapeutics | 7 | - | 50.0M |
| May 26, 2021 | Series C - NiKang Therapeutics | 21 | - | 200.0M |
| Dec 01, 2017 | Series A - NiKang Therapeutics | 1 | - | 10.0M |
Recent Activity
There is no recent news or activity for this profile.